Evidence map›Paper›PMID 39526090›Full record

ArticleSAGE open medicine2024

Factors influencing in-hospital mortality in cancer patients with COVID-19: A retrospective survival analysis.

Sandra Brigitte Amado-Garzón, Luisana Molina-Pimienta, Juan Manuel Vásquez-Jiménez, Karen Lizeth Álvarez-Raigoza, Mauricio Manrique-Samer, Carlos E Lombo-Moreno, Alejandra Cañas-Arboleda

Abstract read
In one paragraph

Article in SAGE open medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sandra Brigitte Amado-GarzónDepartment of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia.ORCID https://orcid.org/0000-0002-7756-1805
Luisana Molina-PimientaDepartment of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia.ORCID https://orcid.org/0000-0001-5505-9710
Juan Manuel Vásquez-JiménezDepartment of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia.ORCID https://orcid.org/0000-0001-8689-9894
Karen Lizeth Álvarez-RaigozaDepartment of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia.ORCID https://orcid.org/0000-0002-8779-6333
Mauricio Manrique-SamerDepartment of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia.ORCID https://orcid.org/0000-0003-0223-0726
Carlos E Lombo-MorenoDepartment of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia.ORCID https://orcid.org/0000-0002-6392-7554
Alejandra Cañas-ArboledaDepartment of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of this study was to evaluate survival in patients with COVID-19 and cancer, and to find factors associated with early mortality. Methods: Retrospective cohort derived from a registry of a referral center in Bogotá. Survival was analyzed according to the type of neoplasm using Kaplan-Meier method. A cox regression was performed to look for factors associated to higher risk of death. Results: Two hundred fifty-four patients were included with cancer and COVID-19, most of whom were women (median age 68 years; range 19-97). Cardiovascular comorbidities were frequent. Patients with hematologic neoplasms had higher survival than those with solid neoplasms (log-rank test, Conclusion: In contrast to other reports, survival was worse in patients with solid tumors than in those with hematologic neoplasms. Increased C-reactive protein, Charlson's comorbidity index and respiratory failure were associated with higher in-hospital mortality. This study reveals the complex impact of cancer and its treatment on COVID-19 outcomes, highlighting the persistent risks to cancer patients. It emphasizes monitoring C-reactive protein levels, comorbidities, and respiratory failure as key indicators of poor prognosis. Furthermore, we provide new insights into the differential impact of COVID-19 on cancer patients with solid organ versus hematologic neoplasms.

Indexed as

cancerCOVID-19hematologicmortalityneoplasm

Identifiers

PMID39526090
PMCPMC11549711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.